Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.

Surgery - 1 Mar 2013

Blackham Aaron U, Northrup Scott A, Willingham Mark, D'Agostino Ralph B, Lyles Douglas S, Stewart John H

Abstract excerpt

BACKGROUND: Vesicular stomatitis virus (VSV) is a novel, anti-cancer therapy that targets cancer cells selectively with defective antiviral responses; however, not all malignant cells are sensitive to the oncolytic effects of VSV. Herein, we have explored the mechanistic determinants of mutant M protein VSV (M51R-VSV) susceptibility in malignant melanoma cells. METHODS: Cell viability after VSV infection was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferon-beta
Share to Melanoma
Share to Mice, Nude

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncolytic Virotherapy

Share to Vesicular stomatitis Indiana virus

Share to Viral Matrix Proteins

Share to Viral Proteins

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 23102637
DOI: 10.1016/j.surg.2012.09.003
PMCID: PMC3561511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.PMID 23102637Read ↗

Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.Semantic proximity Read ↗

Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.Semantic proximity Read ↗

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.Semantic proximity Read ↗

Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.Semantic proximity Read ↗

Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment.Semantic proximity Read ↗

Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cellsSemantic proximity Read ↗

Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.Semantic proximity Read ↗

Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.Semantic proximity Read ↗

Oncolytic Activity of Vesicular Stomatitis Virus Is Effective against Tumors Exhibiting Aberrant p53, Ras, or Myc Function and Involves the Induction of ApoptosisSemantic proximity Read ↗

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.Semantic proximity Read ↗

Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.Semantic proximity Read ↗

Treatment with M51R Vesicular Stomatitis Virus Induces Clonal Antitumor CD8+ T Cell Expansion in Colon CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.